Current Report · Items 2.02, 7.01, 9.01 · 8-K
Traws Pharma, Inc.
TRAWNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02 Results of Operations and Financial Condition. The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings Release is incorporated by reference into this Item 2.02.
Filed Apr 15, 2026Accepted Apr 15, 2026, 4:02 PM EDTCIK 1130598Accession 0001104659-26-043781
Company context
Pharma, Inc. Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.
Current securities
Historical securities (2)
Disclosure sections
Items 2.02, 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
The information provided below in “Item
7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings Release
is incorporated by reference into this Item 2.02.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On April 15, 2026, Traws Pharma, Inc. (the
“Company”) issued a press release (the “Earnings Release”) announcing its financial results for the fiscal year
ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”)
and incorporated herein by reference.
The information set forth under
Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference
language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed
an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Forward-Looking Statements
This Current Report, including
Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms
“anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions,
as they relate to the Company or its management, are intended to identify such forward-looking statements.
Forward-looking statements in this Current Report,
including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission,
reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and
unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating)
or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking
statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results
of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities
and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements
contained herein.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release, dated April 15, 2026
104 Cover
Page Interactive Data File (embedded within the inline XBRL Document)
Filed exhibits (1)
EX-99.1 (by filename) tm2611843d2_ex99-1.htmEX-99.1
2
tm2611843d2_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Traws
Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir
marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral
activity,
Ratutrelvir
topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis
underway
Private financing of up to $60M (with $10M
of such amount upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting
operations into Q1 2027
Investor
Update call today, April 15, 2026 at 4:30 PM ET
NEWTOWN, PA, April
15, 2026 (GLOBE NEWSWIRE) - Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the
Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from
respiratory viral diseases, today reported financial results for the year ended December 31, 2025 and provided recent business highlights
including updates for the Company’s lead investigational program: tivoxavir marboxil (TXM) in developm…
Open exhibit ↗